Tularik Files Registration Statement for Shares Held by ZKB Pharma Vision
Business Editors and Health/Medical Writers
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Jan. 22, 2003
Tularik Inc. (Nasdaq:TLRK) announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the possible resale of up to approximately 11.4 million shares of Tularik common stock owned by ZKB Pharma Vision AG. This registration statement, once declared effective, would permit Pharma Vision to sell its shares at any time and from time to time in one or more private transactions, underwritten secondary offerings, block trades or otherwise as set forth in the registration statement. Pharma Vision is under no legal obligation to sell any of the shares that are being registered. The timing of any sales under this registration statement will be determined by Pharma Vision, taking into consideration its investment policies as well as market conditions.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
A prospectus for the offering, when available, may be obtained by contacting Investor Relations at Tularik Inc., Two Corporate Drive, South San Francisco, CA 94080 or by telephone at (650) 825-7000.
Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik’s scientific platform is focused on three therapeutic areas: cancer, immunology and metabolic disease. The Company currently has three drug candidates in clinical trials. T67 is moving into a pivotal Phase 2/3 study for the treatment of Hepatocellular Carcinoma (HCC) and T607 is in four Phase 2 trials for the treatment of HCC, non-Hodgkin’s lymphoma, ovarian cancer and gastric/esophageal cancer. T487, for the treatment of inflammatory diseases, is in a Phase 1 trial to evaluate safety. This press release contains “forward-looking” statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Tularik to differ materially from those indicated by these forward-looking statements, including, among others, risks detailed from time to time in Tularik’s SEC reports, including the report on Form 10-Q for the quarter ended September 30, 2002 and the report on Form 10-K for the year ended December 31, 2001. Tularik does not undertake any obligation to update forward-looking statements.
COPYRIGHT 2003 Business Wire
COPYRIGHT 2003 Gale Group